2 results match your criteria mds-u pan

  • Page 1 of 1

[Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing].

Zhonghua Xue Ye Xue Za Zhi 2017 Dec;38(12):1012-1016

Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China.

To study the characteristics of gene mutations in Chinese myelodysplastic syndromes (MDS) patients. A total of 511 Chinese patients with MDS performed 112-gene targeted sequencing were retrospectively analyzed. Eighty-three distinct mutant genes were found in 511 patients with MDS. Read More

View Article and Full-Text PDF
December 2017

Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.

Am J Clin Pathol 2017 Jul;148(1):49-57

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY.

Objectives: Three situations qualify as myelodysplastic syndrome, unclassifiable (MDS-U): (1) refractory cytopenia with dysplasia and 1% blasts in peripheral blood (BL), (2) pancytopenia with unilineage dysplasia (Pan), and (3) persistent cytopenia, less than 5% bone marrow blasts, and less than 10% dysplastic cells and presence of MDS-defining cytogenetic abnormalities (CG). We compared the clinicopathologic features and mutational profiles for these three groups.

Methods: MDS-U cases were reviewed at four major academic institutions. Read More

View Article and Full-Text PDF
  • Page 1 of 1